Papers

2

Total Citations

66

H-Index

2

About

Shuiqing Ma is a leading clinical researcher in gynecologic oncology, with a focused expertise in the surgical management of early-stage cervical cancer. Her work is at the forefront of a critical debate in the field: the balance between the benefits of minimally invasive surgery (MIS) and the imperative for optimal oncologic outcomes. Dr. Ma’s major contribution is the design and leadership of pivotal, large-scale randomized controlled trials in China that directly challenge and refine global surgical standards. Her most cited work, a 2019 phase III trial protocol (56 citations), rigorously investigates the efficacy of different surgical approaches—including MIS versus open surgery—for early-stage cervical cancer, a study prompted by the controversial findings of the international LACC trial. She further extends this inquiry into fertility-sparing surgery with a 2020 protocol comparing minimally invasive versus open radical trachelectomy. By spearheading these high-impact, multicenter trials, Dr. Ma is generating the high-level evidence necessary to guide surgeons in selecting the safest, most effective technique, ultimately shaping clinical practice and improving survival outcomes for patients worldwide.

Research Focus

Key Achievements

2
H-Index
2
Papers
66
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
Efficacy of different surgical approaches in the clinical and survival outcomes of patients with early-stage cervical cancer: protocol of a phase III multicentre randomised controlled trial in China
56 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago